gankyrin can cause prostate cancer progression by upregulating octamer-binding protein (NONO) expression, reactivating AR receptors, inducing HMGB1 transcription, and then promoting tumor-associated macrophage aggregation (89). Here, HMGB1 is linked to prostate carcinoma.